MARKET

VKTX

VKTX

Viking Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.33
+0.03
+0.48%
After Hours: 6.39 +0.06 +0.95% 17:55 12/04 EST
OPEN
6.30
PREV CLOSE
6.30
HIGH
6.38
LOW
6.22
VOLUME
751.36K
TURNOVER
--
52 WEEK HIGH
8.87
52 WEEK LOW
3.260
MARKET CAP
461.79M
P/E (TTM)
-12.7339
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Viking Therapeutics to Present at Stifel Healthcare Conference 2020
, /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, , Ph.D., will deliver a corporate presentation as part of the Stifel Healthcare Conference 2020.  The conference, which will take place , is being conducted with a virtual format.
PR Newswire - PRF · 11/10 21:05
Viking Therapeutics EPS beats by $0.02
Viking Therapeutics (VKTX): Q3 GAAP EPS of -$0.13 beats by $0.02. Cash equivalents and short-term investments of $255.3MPress Release
Seekingalpha · 10/28 20:15
Viking Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
, /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended , and provided an update on its clinical pipeline and other corporate developments.
PR Newswire - PRF · 10/28 20:06
Viking Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / October 28, 2020 / Viking Therapeutics, Inc. (NASDAQ:VKTX) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on October 28, 2020 at 4:30 PM Eastern Time.
ACCESSWIRE · 10/28 18:31
The Week Ahead In Biotech: Kala FDA Decision, Merck & Pfizer Earnings, Vaccine Updates And IPOs
Biotech stocks posted weekly declines in the week ended Oct. 23, pressured by the broader market decline amid mixed earnings reports and the impasse on fiscal stimulus.
Benzinga · 10/25 18:42
Viking Therapeutics to Report Financial Results for Third Quarter 2020 on October 28, 2020
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the third quarter 2020, after the market close on Wednesday, October 28, 2020.
PR Newswire · 10/21 21:05
Viking Therapeutics to Report Financial Results for Third Quarter 2020 on October 28, 2020
, Oct. 21, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the third quarter 2020, after the market close on .
PR Newswire - PRF · 10/21 20:05
Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK0214
, /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK0214, a novel, orally available thyroid receptor beta (TRβ) agonist in development as a potential treatment for X-linked adrenoleukodystrophy (X-ALD). Enrollment in this study is underway following clearance of the company's Investigational New Drug (IND) application by the United States Food and Drug Administration (FDA).
PR Newswire - PRF · 09/09 11:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VKTX. Analyze the recent business situations of Viking Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VKTX stock price target is 19.79 with a high estimate of 40.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 227
Institutional Holdings: 45.70M
% Owned: 62.64%
Shares Outstanding: 72.95M
TypeInstitutionsShares
Increased
35
1.93M
New
30
330.13K
Decreased
48
2.88M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Independent Director
Lawson Macartney
President/Chief Executive Officer/Director
Brian Lian
Senior Vice President - Finance/IR Contact Officer
Greg Zante
Vice President - Finance/Vice President - Administration
Michael Morneau
Senior Vice President
Amy Broidrick
Director
Matthew Foehr
Vice President - Finance/Vice President - Operations
Gregory Zante
Vice President
Catherine Kelleher
Independent Director
S. Kathy Rouan
Independent Director
Charles Rowland
Independent Director
Matthew Singleton
Independent Director
J. Matthew Singleton
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Viking Therapeutics Inc stock information, including NASDAQ:VKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VKTX stock methods without spending real money on the virtual paper trading platform.